Literature DB >> 3790495

Stopped-flow kinetic analysis of the interaction of anthraquinone anticancer drugs with calf thymus DNA, poly[d(G-C)].poly[d(G-C)], and poly[d(A-T)].poly[d(A-T)].

C R Krishnamoorthy, S F Yen, J C Smith, J W Lown, W D Wilson.   

Abstract

The sodium dodecyl sulfate driven dissociation reactions of daunorubicin (1), mitoxantrone (2), ametantrone (3), and a related anthraquinone without hydroxyl groups on the ring or side chain (4) from calf thymus DNA, poly[d(G-C)]2, and poly[d(A-T)]2 have been investigated by stopped-flow kinetic methods. All four compounds exhibit biphasic dissociation reactions from their DNA complexes. Daunorubicin and mitoxantrone have similar dissociation rate constants that are lower than those for ametantrone and 4. The effect of temperature and ionic strength on both rate constants for each compound is similar. An analysis of the effects of salt on the two rate constants for daunorubicin and mitoxantrone suggests that both of these compounds bind to DNA through a mechanism that involves formation of an initial outside complex followed by intercalation. The daunorubicin dissociation results from both poly[d(G-C)]2 and poly[d(A-T)]2 can be fitted with a single exponential function, and the rate constants are quite close. The ametantrone and 4 polymer dissociation results can also be fitted with single exponential curves, but with these compounds the dissociation rate constants for the poly[d(G-C)]2 complexes are approximately 10 times lower than for the poly[d(A-T)]2 complexes. Mitoxantrone also has a much slower dissociation rate from poly[d(G-C)]2 than from poly[d(A-T)]2, but its dissociation from both polymers exhibits biphasic kinetics. Possible reasons for the biphasic behavior with the polymers, which is unique to mitoxantrone, are selective binding and dissociation from the alternating polymer intercalation sites and/or dual binding modes of the intercalator with both side chains in the same groove or with one side chain in each groove.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3790495     DOI: 10.1021/bi00368a015

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  Fluorinated anthracyclines: interactions with DNA.

Authors:  K C Tonkin; R C Boston; R T Brownlee; D R Phillips
Journal:  Invest New Drugs       Date:  1990-11       Impact factor: 3.850

2.  In vitro transcription analysis of the role of flanking sequence on the DNA sequence specificity of adriamycin.

Authors:  H Trist; D R Phillips
Journal:  Nucleic Acids Res       Date:  1989-05-25       Impact factor: 16.971

Review 3.  Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent.

Authors:  L H Patterson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

4.  The effect of mitoxantrone as an anticancer drug on hepatocytes nuclei and chromatin: Selective release of histone proteins.

Authors:  Zahra Hajihassan; Azra Rabbani-Chadegani
Journal:  Indian J Pharmacol       Date:  2011-04       Impact factor: 1.200

5.  Mutation induced conformational changes in genomic DNA from cancerous K562 cells influence drug-DNA binding modes.

Authors:  Debjani Ghosh; Subrata Kumar Dey; Chabita Saha
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

6.  Studies on the binding affinity of anticancer drug mitoxantrone to chromatin, DNA and histone proteins.

Authors:  Zahra Hajihassan; Azra Rabbani-Chadegani
Journal:  J Biomed Sci       Date:  2009-03-11       Impact factor: 8.410

7.  Binding mechanism of anti-cancer chemotherapeutic drug mitoxantrone to DNA characterized by magnetic tweezers.

Authors:  Dennis Kreft; Ying Wang; Michael Rattay; Katja Toensing; Dario Anselmetti
Journal:  J Nanobiotechnology       Date:  2018-07-13       Impact factor: 10.435

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.